AI and machine learning are revolutionizing drug discovery, development, and lifecycle management, addressing industry challenges like the "patent cliff" and high clinical failure rates. AI-driven platforms are expected to create most new molecular entities in the next decade, significantly impacting biopharma R&D and market relevance.

Accelerated drug discovery and development platform Converge Bio Inc. today announced it has raised $25 million in early-stage funding to develop better drugs for pharmaceutical companies and open up opportunities in the industry using artificial intelligence.

Lilly and NVIDIA launch AI co-innovation lab to tackle drug discovery challenges.NVIDIA collaborates with Thermo Fisher to build

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years, from the initial phase of identifying potential drug ...

Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The recent acquisition of Exscientia strengthens Recursion's ...

In this interview, Dr. Malika Bsibsi discusses the role of iPSC models in advancing neuroscience drug discovery, focusing on neurodegeneration, neuroinflammation, and innovative in vitro approaches. Could you start by introducing yourself and giving our ...

Experience the forefront of pharmaceutical innovation as Labroots and the Drug Discovery and Development planning committee host the 9th Annual Drug Discovery & Development Virtual Event on February 18th, 2026. Join industry and academic leaders to explore ...

The global drug discovery services market size was US$ 9,112 million in 2021. The global drug discovery services market is forecast to grow to US$ 19,512 million by 2030 by registering a compound annual growth rate (CAGR) of 9.1% during the forecast period from 2022 to 2030.